日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. KLB (JMT202 Biosimilar) Recombinant Monoclonal Antibody

KLB (JMT202 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA769815MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    KLB (JMT202 Biosimilar Antibody)重組單克隆抗體是一款專為科研場景開發(fā)的生物制劑，其核心成分為采用重組DNA技術(shù)制備的單克隆抗體分子。該產(chǎn)品通過先進的哺乳動物細胞表達系統(tǒng)生產(chǎn)，確保抗體分子在氨基酸序列、空間構(gòu)象及生物學(xué)活性等關(guān)鍵特性上的高度一致性與穩(wěn)定性，為生命科學(xué)研究提供可靠的實驗材料支持。 在科研應(yīng)用中，該重組單克隆抗體可廣泛用于靶點驗證、蛋白互作分析、信號通路研究等基礎(chǔ)實驗。其高特異性結(jié)合能力能夠精準識別并結(jié)合目標抗原，有效降低非特異性反應(yīng)對實驗結(jié)果的干擾，適用于ELISA等多種免疫學(xué)檢測方法。此外，產(chǎn)品通過嚴格的質(zhì)量控制流程，包括純度分析、活性測定、內(nèi)毒素檢測等，確保每批次產(chǎn)品的批次間差異最小化，滿足科研實驗對重復(fù)性和準確性的嚴苛要求。 該抗體的研發(fā)遵循標準化生產(chǎn)工藝，從基因克隆、細胞培養(yǎng)到純化工藝均采用符合科研級別的操作規(guī)范，可根據(jù)研究需求提供不同規(guī)格的包裝選擇，靈活適配各類實驗規(guī)模。作為科研用試劑，其設(shè)計理念聚焦于為研究人員提供高性價比的工具，助力在腫瘤學(xué)、免疫學(xué)、神經(jīng)生物學(xué)等多個領(lǐng)域的機制探索與藥物靶點研究，推動基礎(chǔ)科研向臨床轉(zhuǎn)化的前期探索進程。使用時需注意按照產(chǎn)品說明書進行儲存與操作，避免反復(fù)凍融以保持抗體活性，確保實驗數(shù)據(jù)的可靠性與科學(xué)性。
  • Uniprot No.：
  • 基因名：
  • 別名：
    JMT202 research-grade biosimilar ;KLB antibody; Beta-klotho antibody; BKL antibody; BetaKlotho antibody; Klotho beta-like protein antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human KLB protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. Probably inactive as a glycosidase. Increases the ability of FGFR1 and FGFR4 to bind FGF21.
  • 基因功能參考文獻：
    1. Knockdown of beta-Klotho produced the opposite effects. In conclusion, beta-Klotho inhibits EMT and plays a tumorsuppressive role in prostate cancer (PCa) , linking FGF/FGFR/beta-Klotho signaling to the regulation of PCa progression. PMID: 29749458
    2. crystal structures of free and ligand-bound beta-klotho extracellular regions that reveal the molecular mechanism that underlies the specificity of FGF21 towards beta-klotho and demonstrate how the FGFR is activated in a klotho-dependent manner PMID: 29342135
    3. the metabolic FGF21/KLB/FGFR1 pathway is involved in congenital hypogonadotropic hypogonadism (CHH) Genetic screening of 334 CHH patients identified seven heterozygous loss-of-function KLB mutations in 13 patients (4%). Most patients with KLB mutations (9/13) exhibited metabolic defects. PMID: 28754744
    4. We conducted a genome-wide association meta-analysis and replication study among >105,000 individuals of European ancestry and identified beta-Klotho (KLB) as a locus associated with alcohol consumption (rs11940694; P = 9.2 x 10(-12)). PMID: 27911795
    5. A high expression level of KLbeta, but not KLalpha, was an independent predictive factor of short progression free survival for non-muscle invasive bladder cancer PMID: 27573985
    6. Our results suggest that KLbeta plays important roles in tumor invasion and progression, and its concentration may be a valuable urinebased marker for the detection of bladder cancer. PMID: 27573985
    7. obesity appears as the predominant determinant of the abnormalities in FGF21 and FGF19 levels. Opposite changes in beta-Klotho expression in fat and liver indicate potential tissue-specific alterations in the responsiveness to endocrine FGFs in obesity PMID: 24813368
    8. ATF4 signaling pathway is essential for mediating the effect of ER stress on beta-klotho expression. PMID: 25727012
    9. Variants in genes involved in feedback regulation of bile acid synthesis (KLB, P=0.06 and FGFR4, P=0.09) were potentially associated with the irritable bowel syndrome-diarrhea subgroup with elevated serum C4. PMID: 25070056
    10. In-depth DNA sequencing identified additional genetic coding and noncoding variants in KLB that are associated with fecal bile acids excretion or colonic transit in Irritable bowel syndrome-diarrhea. PMID: 24200957
    11. betaKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3beta/cyclin D1 signaling pathway. PMID: 23383245
    12. KLB and FGFR1 form a 1:1 heterocomplex independent of the galectin lattice that transitions to a 1:2 complex upon the addition of FGF21. PMID: 22523080
    13. KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling. PMID: 22439738
    14. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PMID: 22442730
    15. Deletion of the D1 and the D1-D2 linker (the D1/linker region) from FGFR1c led to beta-Klotho-independent receptor activation by FGF21, suggesting that there may be a direct interaction between FGF21 and the D1/linker region-deficient FGFR1c. PMID: 22248288
    16. Polymorphism KLB rs4975017 may influence the colonic transit response to colesevelam in female patients with irritable bowel syndrome with diarrhea. PMID: 22271411
    17. Data suggest that KLB is an important regulator in the immortalization of HCECs by facilitating FGF19 growth factor signaling. PMID: 22020932
    18. Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho. PMID: 21653700
    19. A functional KLB gene variant mediating protein stability associates with colonic transit in irritable bowel syndrome with diarrhea. This association is modulated by 2 genetic variants in FGFR4. PMID: 21396369
    20. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. PMID: 20657013
    21. The down-regulation of the renal klotho gene could increase renal damage induced by angiotensin II, while klotho gene induction could have therapeutic possibilities in treating angiotensin II-induced kidney damage. PMID: 16358222
    22. Liver-specific activities of FGF19 require Klotho beta. PMID: 17627937
    23. a functional FGF19 receptor may consist of FGF receptor (FGFR) and heparan sulfate complexed with either alphaKlotho or betaKlotho PMID: 17711860
    24. High expression of Klotho is associated with ovarian disease progression PMID: 18259951
    25. Both FGF23 and FGF21 require intact alpha or betaKlotho for signaling, respectively, whereas FGF19 can signal through a Klotho chimera consisting of the N terminus of alphaKlotho and the C terminus of betaKlotho. PMID: 18829467
    26. These data demonstrate that the C-terminus of FGF21 is critical for binding to beta-Klotho and the N-terminus is critical for fibroblast growth factor receptor (FGFR) activation. PMID: 19059246

    顯示更多

    收起更多

  • 亞細胞定位：
    Cell membrane; Single-pass type III membrane protein.
  • 蛋白家族：
    Glycosyl hydrolase 1 family, Klotho subfamily
  • 數(shù)據(jù)庫鏈接：

    HGNC: 15527

    OMIM: 611135

    KEGG: hsa:152831

    STRING: 9606.ENSP00000257408

    UniGene: Hs.90756



×
生命科學(xué)計算平臺